Stewart Appelrouth insider trades
Open-market stock purchases and sales by Stewart Appelrouth, Director at AIM ImmunoTech Inc, from SEC Form 4 filings since Apr 12, 2018.
Track record: 83% of 6 scored buys are up 5% or more since purchase, averaging +43%.
Recent trades
No open-market trades in the last 12 months.